Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 With or Without ETBX-071 Vaccine in Biochemically Recurrent Prostate Cancer
NCT07686380Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, adenovirus PSA vaccine in prostate cancer (PCa), sponsored by National Cancer Institute. Started Oct 2026; status: recruiting.
02
Drugs
nogapendekin alfa inbakiceptadenovirus PSA vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07686380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686380.